Shares of Endo International plc – Ordinary Shares (NASDAQ:ENDP) ended Thursday session in green amid volatile trading. The shares closed up +0.35 points or 1.72% at $20.65 with 4.70 million shares getting traded. Post opening the session at $20.35, the shares hit an intraday low of $19.96 and an intraday high of $20.88 and the price vacillated in this range throughout the day. The company has a market cap of $4.52 billion and the numbers of outstanding shares have been calculated to be 222.77 million shares.
Endo International plc – Ordinary Shares (ENDP) on Aug. 18, 2016 announced that Rajiv De Silva, President and CEO, has entered into a Rule 10b5-1 stock trading plan in connection with his year-end tax planning. Under the terms of Mr. De Silva’s stock trading plan, an authorized third-party broker will sell up to 13,500 Endo shares beneficially owned by Mr. De Silva, which represents approximately 4 percent of Mr. De Silva’s total Endo stock ownership. The stock trading plan will be completed in September 2016. If all of the planned Endo share sales under Mr. De Silva’s stock trading plan are completed, Mr. De Silva will continue to beneficially own Endo shares with an aggregate market value well in excess of five times his base salary, as required by the Company’s stock ownership guidelines.
The stock trading plan executed by Mr. De Silva was adopted in accordance with Endo’s insider trading policy and the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, which provides an affirmative defense from potential liability for company insiders by permitting them to buy or sell a predetermined amount of their company’s shares as set forth in a planned acquisition or divestiture program which is adopted when the insider does not possess material non-public information. Transactions under Mr. De Silva’s stock trading plan and any other insiders’ stock trading plans will be publicly reported to the U.S. Securities and Exchange Commission in accordance with applicable securities laws, rules and regulations.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Thursday session in red amid volatile trading. The shares closed down -0.31 points or -1.02% at $29.96 with 11.59 million shares getting traded. Post opening the session at $30.24, the shares hit an intraday low of $29.72 and an intraday high of $30.58 and the price vacillated in this range throughout the day. The company has a market cap of $10.51 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
Valeant Pharmaceuticals Intl Inc (VRX) on Sept. 6, 2016 announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa, Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”